Dai et al. [132] reported that six patients with B-ALL who received a tandem infusion of CD19/CD22-targeted CAR-T cells all achieved MRD-negative CR and experienced grade 1 or 2 CRS; none of the patients experienced neurotoxicity. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.